Stockreport

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis

Forte Biosciences, Inc.  (FBRX) 
PDF TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the [Read more]